Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 240

1.

Developmental Milestones in Pediatric Research; A Case for Including Efficacy as Part of Interventional Trials in Infants with Cystic Fibrosis.

Sanders DB, Nichols DP.

Am J Respir Crit Care Med. 2018 Nov 13. doi: 10.1164/rccm.201811-2103ED. [Epub ahead of print] No abstract available.

PMID:
30422678
2.

A population of luminous accreting black holes with hidden mergers.

Koss MJ, Blecha L, Bernhard P, Hung CL, Lu JR, Trakthenbrot B, Treister E, Weigel A, Sartori LF, Mushotzky R, Schawinski K, Ricci C, Veilleux S, Sanders DB.

Nature. 2018 Nov;563(7730):214-216. doi: 10.1038/s41586-018-0652-7. Epub 2018 Nov 7.

PMID:
30405225
3.

Quantitative chest computerized tomography and FEV1 equally identify pulmonary exacerbation risk in children with cystic fibrosis.

Sanders DB, Li Z, Parker-McGill K, Farrell P, Brody AS.

Pediatr Pulmonol. 2018 Oct;53(10):1369-1377. doi: 10.1002/ppul.24144. Epub 2018 Aug 29.

PMID:
30160050
4.

Reply.

Nandedkar SD, Sanders DB, Hobson-Webb LD, Billlakota S, Barkhaus PE, Stalberg EV.

Muscle Nerve. 2018 Oct;58(4):E31-E32. doi: 10.1002/mus.26198. Epub 2018 Sep 18. No abstract available.

PMID:
30043996
5.

Randomized study of adjunctive belimumab in participants with generalized myasthenia gravis.

Hewett K, Sanders DB, Grove RA, Broderick CL, Rudo TJ, Bassiri A, Zvartau-Hind M, Bril V; BEL115123 Study Group.

Neurology. 2018 Apr 17;90(16):e1425-e1434. doi: 10.1212/WNL.0000000000005323. Epub 2018 Mar 21.

6.

Problems in Comparing Jitter Values Obtained with Voluntary Activation and Electrical Stimulation.

Stålberg E, Kouyoumdjian JA, Paiva GP, Yanaze LL, Sanders DB.

J Neuromuscul Dis. 2018;5(2):225-230. doi: 10.3233/JND-170289.

PMID:
29614693
7.

Reply.

Sanders DB, Harati Y, Juel VC, Lou JS, Marburger T, Pascuzzi RM, Peltier AC, Richman DP, Smith AG.

Muscle Nerve. 2018 May;57(5):E130-E131. doi: 10.1002/mus.26089. Epub 2018 Mar 1. No abstract available.

PMID:
29406616
8.

Early life growth patterns persist for 12 years and impact pulmonary outcomes in cystic fibrosis.

Sanders DB, Zhang Z, Farrell PM, Lai HJ; Wisconsin CF Neonatal Screening Group.

J Cyst Fibros. 2018 Jul;17(4):528-535. doi: 10.1016/j.jcf.2018.01.006. Epub 2018 Feb 1.

PMID:
29396025
9.

Developing treatment guidelines for myasthenia gravis.

Sanders DB, Wolfe GI, Narayanaswami P; MGFA Task Force on MG Treatment Guidance.

Ann N Y Acad Sci. 2018 Jan;1412(1):95-101. doi: 10.1111/nyas.13537. Review.

PMID:
29381223
10.

Comparative effectiveness clinical trials to advance treatment of myasthenia gravis.

Guptill JT, Raja S, Sanders DB, Narayanaswami P.

Ann N Y Acad Sci. 2018 Feb;1413(1):69-75. doi: 10.1111/nyas.13582. Epub 2018 Jan 28. Review.

PMID:
29377158
11.

3,4-diaminopyridine base effectively treats the weakness of Lambert-Eaton myasthenia.

Sanders DB, Juel VC, Harati Y, Smith AG, Peltier AC, Marburger T, Lou JS, Pascuzzi RM, Richman DP, Xie T, Demmel V, Jacobus LR, Aleš KL, Jacobus DP; Dapper Study Team.

Muscle Nerve. 2018 Apr;57(4):561-568. doi: 10.1002/mus.26052. Epub 2018 Feb 2.

12.

Study design considerations for the Standardized Treatment of Pulmonary Exacerbations 2 (STOP2): A trial to compare intravenous antibiotic treatment durations in CF.

Heltshe SL, West NE, VanDevanter DR, Sanders DB, Beckett VV, Flume PA, Goss CH; STOP Study Group.

Contemp Clin Trials. 2018 Jan;64:35-40. doi: 10.1016/j.cct.2017.11.012. Epub 2017 Nov 21.

13.

Longitudinal development of initial, chronic and mucoid Pseudomonas aeruginosa infection in young children with cystic fibrosis.

Heltshe SL, Khan U, Beckett V, Baines A, Emerson J, Sanders DB, Gibson RL, Morgan W, Rosenfeld M.

J Cyst Fibros. 2018 May;17(3):341-347. doi: 10.1016/j.jcf.2017.10.008. Epub 2017 Oct 28.

PMID:
29110966
14.

Pitfalls and errors in measuring jitter.

Stålberg E, Sanders DB, Kouyoumdjian JA.

Clin Neurophysiol. 2017 Nov;128(11):2233-2241. doi: 10.1016/j.clinph.2017.09.001. Epub 2017 Sep 21. Review.

PMID:
29017138
15.

Poor recovery from cystic fibrosis pulmonary exacerbations is associated with poor long-term outcomes.

Sanders DB, Zhao Q, Li Z, Farrell PM.

Pediatr Pulmonol. 2017 Oct;52(10):1268-1275. doi: 10.1002/ppul.23765. Epub 2017 Sep 7.

16.

Poor recovery from a pulmonary exacerbation does not lead to accelerated FEV1 decline.

Sanders DB, Li Z, Zhao Q, Farrell PM.

J Cyst Fibros. 2017 Jul 29. pii: S1569-1993(17)30818-4. doi: 10.1016/j.jcf.2017.07.003. [Epub ahead of print]

PMID:
28765072
17.

Reliability of the triple-timed up-and-go test.

Sanders DB, Guptill JT, Aleš KL, Hobson-Webb LD, Jacobus DP, Mahmood R, Massey JM, Pittman MM, Prather K, Raja SM, Yow E, Juel VC.

Muscle Nerve. 2018 Jan;57(1):136-139. doi: 10.1002/mus.25700. Epub 2017 Jun 6.

18.

Standardized Treatment of Pulmonary Exacerbations (STOP) study: Observations at the initiation of intravenous antibiotics for cystic fibrosis pulmonary exacerbations.

Sanders DB, Solomon GM, Beckett VV, West NE, Daines CL, Heltshe SL, VanDevanter DR, Spahr JE, Gibson RL, Nick JA, Marshall BC, Flume PA, Goss CH; STOP Study Group.

J Cyst Fibros. 2017 Sep;16(5):592-599. doi: 10.1016/j.jcf.2017.04.005. Epub 2017 Apr 29.

19.

Standardized Treatment of Pulmonary Exacerbations (STOP) study: Physician treatment practices and outcomes for individuals with cystic fibrosis with pulmonary Exacerbations.

West NE, Beckett VV, Jain R, Sanders DB, Nick JA, Heltshe SL, Dasenbrook EC, VanDevanter DR, Solomon GM, Goss CH, Flume PA; STOP investigators.

J Cyst Fibros. 2017 Sep;16(5):600-606. doi: 10.1016/j.jcf.2017.04.003. Epub 2017 Apr 29.

PMID:
28457954
20.

Rationalizing endpoints for prospective studies of pulmonary exacerbation treatment response in cystic fibrosis.

VanDevanter DR, Heltshe SL, Spahr J, Beckett VV, Daines CL, Dasenbrook EC, Gibson RL, Raksha J, Sanders DB, Goss CH, Flume PA; STOP Study Group.

J Cyst Fibros. 2017 Sep;16(5):607-615. doi: 10.1016/j.jcf.2017.04.004. Epub 2017 Apr 21.

PMID:
28438499

Supplemental Content

Loading ...
Support Center